Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 4/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1637155 | 0.93 | CXCR4 (0.44) | CXCR4DRD2LTA4HTAAR1CTSD | |
| SCHEMBL1638559 | 0.92 | CXCR4 (0.48) | CXCR4TAAR1CTSD | |
| SCHEMBL1636559 | 0.91 | CXCR4 (0.43) | CXCR4PPARGPPARACTSD | |
| SCHEMBL1637121 | 0.89 | CXCR4 (0.45) | CXCR4DRD2TAAR1 | |
| SCHEMBL1638158 | 0.89 | CXCR4 (0.41) | CXCR4PPARGPPARACTSD | |
| SCHEMBL1637226 | 0.89 | CXCR4 (0.57) | CXCR4LTA4HTP53CTSD | |
| SCHEMBL1637214 | 0.89 | CXCR4 (0.48) | CXCR4TAAR1CTSD | |
| SCHEMBL1638011 | 0.89 | CXCR4 (0.42) | CXCR4DRD2LTA4HPPARGPPARA | |
| SCHEMBL1637975 | 0.89 | CXCR4 (0.51) | CXCR4PPARGPPARATAAR1 | |
| SCHEMBL1637481 | 0.88 | CXCR4 (0.41) | CXCR4PPARGPPARATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | KUREHA CORPORATION (JP) | 2011-07-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | NR0B2, NR5A2, NR1D2 | CXCR4 86/4885DRD2 175/4885LTA4H 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.